China has banned the import of Illumina’s next-generation sequencing (NGS) sequencers as part of retaliatory measures against ...

Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...

Next-generation sequencing (NGS) has moved away from expensive runs ... In this Innovation Spotlight, Emmanuel Naouri, associate director of Product Management, NGS Benchtop Systems at Illumina, ...

The ‘omics’ field has advanced spectacularly since then, fueled by the advent of next-generation sequencing (NGS) and related ... by the summit sponsors – Illumina, Sampled, Scale ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...

The MiSeq desktop sequencer offers low throughput flowcells and long read lengths. It is best for small whole-genome sequencing, targeted gene sequencing, metagenomics, and CRISPR validation. The ...

which analysts believe could significantly expand Illumina's Total (EPA:TTEF) Addressable Market (TAM) by making it easier for new Next-Generation Sequencing (NGS) customers to enter the market.

China banned the import of Illumina Inc. gene-sequencing machines as part of a wave of retaliatory measures against fresh US tariffs on all Chinese goods, deepening the US company’s woes in one ...

(RTTNews) - Illumina, Inc. (ILMN) responded on Monday to the notice from the China Ministry of Commerce stating that it is not permitted to export sequencing instruments into China. Illumina said ...

Medical Device Network · JHVEPhoto via Shutterstock. China has banned the import of Illumina’s next-generation sequencing (NGS) sequencers as part of retaliatory measures against fresh tariffs ...